BioSpace News Archive

The global market for hospital acquired diseases testing market is anticipated to gather momentum on account of the growing awareness about health, hygiene, and wellness amongst the masses.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Gynecological diseases represent a collective term given to different medical conditions specific to the female reproductive system.

According to Transparency Market Research’s latest report on the global gene therapy market for the historical period 2017–2019 and forecast period 2021–2028, promising therapeutic outcomes, new product approvals & commercialization, high prevalence, and increase in incidence of cancer are projected to drive the global gene therapy market during the forecast period.

After the first case of monkeypox was reported in the UK in early May, according to data compiled by the US CDC on July 1, 5,783 cases of monkeypox have been reported in 52 countries.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its half year 2022 financial results and provided a second quarter business update.

Celyad Oncology SA announced that the Company will report first half 2022 financial and operating results on the morning of Friday, August 5, 2022.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conference: BTIG Biotechnology Conference, New-York Event Date: August 8-9, 2022 About Innate Pharma: Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Ipsen, a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results Strong sales growth of 10.5% at CER1 Core operating margin of 39.6%; IFRS operating margin of 35.7% Core consolidated net profit of €420m, growing by 19.9%.

Genentech, a member of the Roche Group, announced that data from 41 abstracts across its portfolio of Alzheimer’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Association International Conference, which will be held in San Diego from July 31 - Aug. 4, 2022.

Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease.